Repros' Proellex Shows Statistically Significant Improvement in
Primary Endpoint in Phase 2 Trial in the Treatment of Uterine
THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros
Therapeutics Inc. (NasdaqGM:RPRX) announced final results of a U.S.
Phase 2 study of Proellex(TM), an oral drug being developed to
relieve symptoms of uterine fibroids. This study suggests that
treatment with Proellex
results in a statisti...
Repros Reports That Proellex Has Demonstrated Superior Efficacy and
Safety in Endometriosis When Compared to Standard of Drug Care
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - Repros
Therapeutics Inc. (NasdaqGM:RPRX) today released top-line findings
from its six month study of Proellex
in the treatment of
endometriosis. This study, conducted in Europe, enrolled 39
premenopausal women and has completed six months of do...
Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits
Potential for New Approach to the Treatment and Prevention of
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - Repros
Therapeutics Inc. (NasdaqGM:RPRX) today announced that an article
has been published in the July 1, 2007 issue of Oncology Reports
indicating a potential for a new approach to the treatment of
breast cancer using Proellex. The article revi...
Repros' Androxal Shows Highly Statistically Significant Positive
Effects in Men with Secondary Hypogonadism
...ine fibroids, a condition that affects numerous
women of childbearing age in the U.S. and results in a significant
number of hysterectomies each year. proellex
is also being studied
in a six month European Phase 1/2 study for the treatment of
endometriosis, a condition that affects approximately 5.5 million